Elucid Vivo provides clinical solutions based on histology & machine learning. We provide solutions for lipid rich necrotic core, atherosclerotic plaque, CTA plaque analysis, risk of heart attack, and stroke.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $107M
Investors 3
| Date | Name | Website |
| 02.06.2022 | BlueStone ... | bluestonev... |
| - | Biovision ... | biovision.... |
| - | Bioverge | ventures.b... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.11.2023 | Series C | $80M | - |
| 23.06.2022 | Series B | $27M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.11.2023 | Elucid collects $80M for AI-powered mapping of blocked arteries | The cardiovascular imaging company Elucid has made it clear they mean to deliver on their promise of artificial intelligence-powered exams to chart the insides of blocked arteries. And now they’ve raised $80 million to do so. Financially sp... |
| 10.11.2023 | Elucid Raises $80M to Drive Commercialization of AI-powered Cardiovascular Diagnostic Tools | What You Should Know: – Elucid, a medical technology company providing AI-powered imaging analysis software to assess cardiovascular disease, has raised $80M in Series C funding led by Elevage Medical Technologies, with additional participa... |
| 09.11.2023 | Elucid Raises $80M in Series C Funding | Elucid, a Boston, MA-based medical technology company, raised $80M in Series C funding. The round, which brought the total amount to $121M, was led by Elevage Medical Technologies, with participation from other investors. ì The company inte... |
| 24.06.2022 | Elucid clears $27M funding for heart disease diagnostic AI | No, it’s not a dream—Boston-based startup Elucid has closed its largest fundraising session yet, a funding round that more than triples the $8 million series A it unveiled around this time last year. The new series B clocks in at $27 millio... |
| 23.06.2022 | Elucid Raises $27M in Series B Funding | Elucid, a Boston, MA-company developing non-invasive medical software to characterize cardiovascular disease, raised $27M in Series B funding. The round was led by an undisclosed strategic investor, with participation from Biovision Venture... |
| - | Elucid | “Elucid delivers personalized patient care with the only objective and quantitative CTA-based arterial analysis software.” |